Answers are grounded in this paper and cite their sources.
Bosentan is associated with adverse hepatic effects. To minimize such risk, regulators implemented risk minimization measures (RMMs), including testing for liver injury biomarkers (alanine and aspartate transaminase and bilirubin) prior to therapy initiation and monthly throughout therapy. This study aimed to examine the adherence to hepatic monitoring requirements.
No takes yet. Share an insight, caveat, or question.
Alyami et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: